Ed Cannon, a veteran executive in the life sciences industry, is the new chief executive officer at venture-backed AerovectRx Corporation.
AerovectRx is a developer of aerosol drug delivery and other technology. It received approval from the U.S. Food and Drug Administration to begin marketing of its technology for its disposal medication cartridge last year. The device is designed to deliver drugs that would otherwise have to be injected.
Cannon will be charged with securing more Series A venture financing for the company in addition to pursuing clinical trials of its technology.
Georgia Venture Partners, Emergent Growth Fund, and the Advanced Technology Development Center Seed Fund made an undisclosed investment in the company in September of 2006.
AerovectRx has developed AeroCell for delivery of therapeutics and vaccines through the respiratory tract. The company is a spinout of the Centers for Disease Control.
Cannon has served as an executive at AdipoGenix, Elixir Pharmaceuticals, and Hygeia Sciences. He received a doctorate degree in biochemistry at the University of Georgia and trained in molecular immunology at Harvard Medical School.
